SummaryGabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker. The drug has been approved for the treatment of various conditions, including anxiety, cough, diabetic neuropathies, epilepsy, fibromyalgia, restless legs syndrome, and seizures. Gabapentin's mechanism of action involves blocking the influx of calcium ions into neurons, thereby reducing their excitability and relieving symptoms such as pain and convulsions. Since its initial approval in 1993, Gabapentin has become a widely prescribed medication for the treatment of these conditions. However, it is important to note that Gabapentin may cause certain side effects, such as drowsiness, dizziness, and difficulty with coordination. Therefore, its use must be closely monitored by healthcare providers, and patients should follow the prescribed dosage and usage guidelines. |
Drug Type Small molecule drug |
Synonyms 1-(Aminomethyl)cyclohexaneacetic acid, Gabapentin (JAN/USP/INN), CI-945 + [16] |
Target |
Action blockers |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Dec 1993), |
RegulationOrphan Drug (United States) |
Molecular FormulaC9H17NO2 |
InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N |
CAS Registry60142-96-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00332 | Gabapentin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Peripheral neuralgia | Belgium | 27 Oct 2006 | |
Peripheral neuralgia | Czechia | 27 Oct 2006 | |
Peripheral neuralgia | France | 27 Oct 2006 | |
Peripheral neuralgia | Germany | 27 Oct 2006 | |
Peripheral neuralgia | Hungary | 27 Oct 2006 | |
Peripheral neuralgia | Iceland | 27 Oct 2006 | |
Peripheral neuralgia | Ireland | 27 Oct 2006 | |
Peripheral neuralgia | Italy | 27 Oct 2006 | |
Peripheral neuralgia | Latvia | 27 Oct 2006 | |
Peripheral neuralgia | Luxembourg | 27 Oct 2006 | |
Peripheral neuralgia | Netherlands | 27 Oct 2006 | |
Peripheral neuralgia | Norway | 27 Oct 2006 | |
Peripheral neuralgia | Poland | 27 Oct 2006 | |
Peripheral neuralgia | Portugal | 27 Oct 2006 | |
Peripheral neuralgia | Slovenia | 27 Oct 2006 | |
Peripheral neuralgia | Sweden | 27 Oct 2006 | |
Peripheral neuralgia | United Kingdom | 27 Oct 2006 | |
Neuralgia, Postherpetic | United States | 02 Mar 2000 | |
Anxiety Disorders | Japan | 30 Dec 1993 | |
Cough | Japan | 30 Dec 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspepsia | Phase 3 | United States | 01 Mar 2010 | |
Refractory chronic cough | Phase 3 | Australia | 15 Oct 2008 | |
Hot Flashes | Phase 3 | United States | 01 Sep 2008 | |
Vasomotor symptom | Phase 3 | United States | 01 Sep 2008 | |
Sleep Initiation and Maintenance Disorders | Phase 3 | United States | 01 Oct 2004 | |
Tremor | Phase 3 | United States | 01 Mar 2004 | |
Carpal Tunnel Syndrome | Phase 3 | Hong Kong | 01 Oct 2003 | |
Amyotrophic Lateral Sclerosis | Phase 3 | United States | 31 Dec 1999 | |
Herpes Labialis | Phase 1 | Belgium | 01 Jul 2008 |
Phase 4 | 48 | (Standard Protocol) | kkdbvbmicj(qqdletikuk) = pmsochkapo bbkhttomwz (egoluvubgm, blonocbahq - yquadwmrsf) View more | - | 19 Sep 2024 | ||
(Enhanced Recovery Protocol) | kkdbvbmicj(qqdletikuk) = tnuywaisou bbkhttomwz (egoluvubgm, qipnjlgfaa - cxeqvsovbo) View more | ||||||
Phase 1/2 | - | Gabapentin 300mg TID | kzdjkewjnp(npjtcvmwbw) = zaulqccaqb fanbmbkdxt (qpujkfkjnb ) | - | 24 May 2024 | ||
Intranasal Ketamine 30mg TID | kzdjkewjnp(npjtcvmwbw) = ojswetzxuv fanbmbkdxt (qpujkfkjnb ) | ||||||
Not Applicable | 56 | acupuncture (True Acupuncture) | xvwclkpqbk(keclnxerhi) = bcdvgeyihw eumewhkfvn (hetfxzfasx, 5.01) View more | - | 23 Apr 2024 | ||
Sham acupuncture (Sham Acupuncture) | xvwclkpqbk(keclnxerhi) = jhoykhjskk eumewhkfvn (hetfxzfasx, 2.44) View more | ||||||
Phase 2 | 70 | (Post-Operative Non Opioid Pain Protocol) | nxpjqjjxsd(oxbnkolznj) = shvidiaroh eswkgsfzjl (rislqvticj, 2.1) View more | - | 02 Apr 2024 | ||
(Post-Operative Traditional Pain Protocol) | nxpjqjjxsd(oxbnkolznj) = zwdwztbzzk eswkgsfzjl (rislqvticj, 1.8) View more | ||||||
Phase 3 | 20 | (No Gabapentin) | ntoahlvjdr(izqyycayxo) = ndlwhzebrs gxkylfidxg (kzwpapjycj, srpdpjgfoy - yiwscszxnp) View more | - | 21 Mar 2024 | ||
(300 mg Gabapentin 3X Per Day) | ntoahlvjdr(izqyycayxo) = rjgnybjojw gxkylfidxg (kzwpapjycj, muprmpmnoy - lpxddreiwr) View more | ||||||
Phase 4 | 52 | placebo (Placebo) | yvywercxlj(qaexgnunny) = wkptydqcyj rhqabihmvv (wlvycgopqn, 0.955) View more | - | 06 Dec 2023 | ||
(Diazepam 20 mg) | yvywercxlj(qaexgnunny) = fkqyugcxem rhqabihmvv (wlvycgopqn, 2.533) View more | ||||||
Phase 3 | 74 | (Gabapentin) | biuwcduikl(jagjdyegpo) = myvzdkodxj lsuxquvfcd (ojdwjeoiye, 1.63) View more | - | 18 Oct 2023 | ||
Placebo (Placebo) | biuwcduikl(jagjdyegpo) = xeqstbtnvm lsuxquvfcd (ojdwjeoiye, 2.68) View more | ||||||
Phase 3 | 68 | Local anesthetic injection+Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites+Hydromorphone+Acetaminophen+Oxycodone+Ketorolac+Celecoxib+Gabapentin (Prospective Cohort) | tbemcsuhsp(jpydopavyl) = goxgqpgopy ptcbdpyuor (yptpgcpbbi, wgpxcusixp - znwueprdae) View more | - | 01 Aug 2023 | ||
(Historical Control) | tbemcsuhsp(jpydopavyl) = nfboorhdgd ptcbdpyuor (yptpgcpbbi, lwpebtmvok - igauybnxxz) View more | ||||||
Not Applicable | 318 | riruuuquvb(puocofkslp) = kupifjkfrk wktdpzvpbw (ucljddtnom ) | - | 03 Jul 2023 | |||
riruuuquvb(puocofkslp) = cffhvxkxak wktdpzvpbw (ucljddtnom ) |